Stay updated on Masitinib Plus Docetaxel in mCRPC Clinical Trial
Sign up to get notified when there's something new on the Masitinib Plus Docetaxel in mCRPC Clinical Trial page.

Latest updates to the Masitinib Plus Docetaxel in mCRPC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page history shows a new revision entry (v3.3.2) added and the previous revision (v3.3.1) removed, which is a minor maintenance update to the record history and does not affect study details or status. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedRevision: v3.3.1 was added and Revision: v3.2.0 was removed in the Record History. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check29 days agoChange DetectedRemoved the government funding lapse notice, which warned that information may not be up to date, and this change does not affect core trial information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check43 days agoChange DetectedA new version entry (Version 9, dated 2023-09-27) appears in the Record History, updating the page's revision log. This is a routine log update and does not modify the study's substantive details or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check72 days agoChange DetectedUpgrade to version v3.2.0 with a prominent government funding operating-status notice; v3.1.0 reference removed.SummaryDifference13%

- Check79 days agoChange DetectedUpgrade noted: from v3.0.2 to v3.1.0, updating the page version. No other substantive content changes are indicated.SummaryDifference0.3%

Stay in the know with updates to Masitinib Plus Docetaxel in mCRPC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Masitinib Plus Docetaxel in mCRPC Clinical Trial page.